1. About the Company
Windlas Biotech operates as a leading CDMO player in India's generic pharmaceutical space. Founded in 2001 and listed in August 2021, the firm operates five WHO-GMP compliant manufacturing units from its Dehradun headquarters.
- Commissioning injectable facilities in FY25
- Plant-2 capacity extension for oral solids
- Plant-6 added for future expansion
- Highest-ever EPS post-listing in FY25: ₹29.2
2. Business Segments
Generic Formulations CDMO (73% of FY25 revenue): 5-year revenue CAGR of 14%, 99% product IP owned by Windlas, 757 customers and 5,582 brands.
Trade Generics & Institutional (23%): 5-year CAGR of 40%+, 400 brands across 29 states, 1,095 direct stockists.
Exports (4%): FY25 revenue ₹33 Cr (+19% YoY), presence in semi-regulated markets.
3. P&L Analysis
Revenue trajectory shows growth from ₹352 Cr (FY18) to ₹760 Cr (FY25), representing ~11.5% CAGR. Operating margins remained stable in the 10–13% range.
4. Balance Sheet Analysis
The company maintains a net-cash position with ₹495 Cr reserves and ₹33 Cr debt. Asset turnover reaches 1.1x.
5. Key Growth Drivers
Injectable Facility Commercialisation: The ₹75 Cr plant generates revenue starting FY25, with significant ramp-up expected in FY26–27.
Trade Generics Scale-Up: 1,000+ stockists position Windlas advantageously for generic penetration in Tier 2–3 markets.
Schedule M Regulatory Tailwind: Post-2021 stricter enforcement eliminated non-compliant manufacturers.
6. Conclusion
Windlas evolves into a capital-efficient, multi-vertical pharmaceutical enterprise demonstrating strong fundamentals.
This is not stock advice. Content is for informational and research purposes only.
